RHOBTB2 (Rho-related BTB domain-containing protein 2) is a member of the Rho GTPase family, which regulates cytoskeletal dynamics, intracellular trafficking, and cell cycle progression. Unlike typical Rho GTPases, RHOBTB2 contains a unique N-terminal BTB (Broad-Complex, Tramtrack, Bric-a-brac) domain, enabling interactions with Cullin-3 E3 ubiquitin ligase complexes to mediate protein degradation. It functions as a tumor suppressor, with roles in vesicular transport, cell polarity, and apoptosis. Dysregulation of RHOBTB2 is implicated in cancers, neurodegenerative disorders, and hypertension.
RHOBTB2 antibodies are essential tools for studying its expression, localization, and molecular interactions. These antibodies are typically generated against specific epitopes, such as the C-terminal region or BTB domain, and validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Research using RHOBTB2 antibodies has revealed its cytoplasmic and perinuclear distribution, as well as its involvement in ubiquitin-mediated proteolysis pathways. Studies also highlight its role in suppressing tumor growth by promoting the degradation of oncoproteins like Cyclin E. However, antibody specificity remains a challenge due to sequence homology within the RhoBTB subfamily. Reliable RHOBTB2 antibodies are critical for advancing insights into its pathophysiological mechanisms and therapeutic potential.